Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

62.94 +3.87 (+6.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Via The Motley Fool
Market Whales and Their Recent Bets on CRSP Options
 
Via Benzinga
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most
 
Via Benzinga
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.< 
Via Benzinga
Topics Artificial Intelligence
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Via The Motley Fool
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
The Ultimate Healthcare Stock to Buy With $500 Right Now
Via The Motley Fool
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
Via The Motley Fool
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Via The Motley Fool
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Via The Motley Fool
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
3 Unstoppable Stocks to Buy in 2025
Via The Motley Fool
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares. 
Via Benzinga
Topics Artificial Intelligence
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Via The Motley Fool
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback